First Evidence for a Dose–Response Relationship in Patients Treated with 166Ho Radioembolization: A Prospective Study

Remco Bastiaannet, Caren van Roekel, Maarten L. J. Smits, Sjoerd G. Elias, Wouter A. C. van Amsterdam, Dieu Ni Doan, Jip F. Prince, Rutger C. G. Bruijnen, Hugo W. A. M. de Jong, Marnix G. E. H. LamJournal of Nuclear Medicine 2019 · DOI

Abstract

<sup>166</sup>Ho-microspheres have recently been approved for clinical use for hepatic radioembolization in the European Union. The aim of this study was to investigate the absorbed dose-response relationship and its association with overall survival for <sup>166</sup>Ho radioembolization in patients with liver metastases. <b>Methods:</b> Patients treated in the HEPAR I and II studies who underwent an <sup>18</sup>F-FDG PET/CT scan at baseline, a posttreatment <sup>166</sup>Ho SPECT/CT scan, and another <sup>18</sup>F-FDG PET/CT scan at the 3-mo follow-up were included for analysis. The posttreatment <sup>166</sup>Ho-microsphere activity distributions were estimated with quantitative SPECT/CT reconstructions using a quantitative Monte Carlo-based method. The response of each tumor was based on the change in total lesion glycolysis (TLG) between baseline and follow-up and was placed into 1 of 4 categories, according to the PERCIST criteria, ranging from complete response to progressive disease. Patient-level response was grouped according to the average change in TLG per patient. The absorbed dose-response relationship was assessed using a linear mixed model to account for correlation of tumors within patients. Median overall survival was compared between patients with and without a metabolic liver response, using a log-rank test. <b>Results:</b> Thirty-six patients with a total of 98 tumors were included. The relation between tumor-absorbed dose and both tumor-level and patient-level response was explored. At a tumor level, a significant difference in geometric mean absorbed dose was found between complete response (232 Gy; 95% confidence interval [CI], 178-303 Gy; <i>n</i> = 32) and stable disease (147 Gy; 95% CI, 113-191 Gy; <i>n</i> = 28) (<i>P</i> = 0.01) and between complete response and progressive disease (117 Gy; 95% CI, 87-159 Gy; <i>n</i> = 21) (<i>P</i> = 0.0008). This constitutes a robust absorbed dose-response relationship. At a patient level, a significant difference was found between patients with complete or partial response (210 Gy; 95% CI, 161-274 Gy; <i>n</i> = 13) and patients with progressive disease (116 Gy; 95% CI, 81-165 Gy; <i>n</i> = 9) (<i>P</i> = 0.01). Patients were subsequently grouped according to their average change in TLG. Patients with an objective response (complete or partial) exhibited a significantly higher overall survival than nonresponding patients (stable or progressive disease) (median, 19 mo vs. 7.5 mo; log-rank, <i>P</i> = 0.01). <b>Conclusion:</b> These results confirm a significant absorbed dose-response relationship in <sup>166</sup>Ho radioembolization. Treatment response is associated with a higher overall survival.
BibTeX
@article{bastiaannet2019first,
  author = {Remco Bastiaannet and Caren van Roekel and Maarten L. J. Smits and Sjoerd G. Elias and Wouter A. C. van Amsterdam and Dieu Ni Doan and Jip F. Prince and Rutger C. G. Bruijnen and Hugo W. A. M. de Jong and Marnix G. E. H. Lam},
  title = {{First Evidence for a Dose–Response Relationship in Patients Treated with <sup>166</sup>Ho Radioembolization: A Prospective Study}},
  journal = {Journal of Nuclear Medicine},
  year = {2019},
  doi = {10.2967/jnumed.119.232751},
}

Loading related content...

Figure